

RESEARCH FUNDING – Grant Support Information

GRANTS

Characterization and Potential Role of NK and NK-T cells in the Host Defense against Malignant Glioma. Submitted to The Brain Tumor Honor Society. 2006.
Principal Investigators: Gail Skowron, M.D., Prakash Sampath, M.D.

Chimeric IL-13 / T-cell receptor "Designer" T cells Against Experimental Malignant Gliomas. Submitted to National Brain Tumor Foundation (NBTF). 2007.
Principal Investigators: Prakash Sampath, M.D.

"Designer" T cells Against Malignant Brain Tumors. Submitted to Center for Biomedical Research Excellence (COBRE). Submitted to NIH 2007.

Novel Treatments for Malignant Brain Tumors. NIH National Research Service Award CA-09574-12 (\$50,000). 1996-1997.

Novel Treatments for Malignant Brain Tumors. NIH National Research Service Award CA-09574-13 (\$50,000). 1997-1998.

CLINICAL TRIALS AND ANIMAL PROTOCOLS

Animal Protocols

Co-Principal Investigator, Experimental model for gene delivery to treat malignant CNS tumor. (Del la Monte S, Sampath P)
Approved: 8/2000. Lifespan ARB.

Co-Principal Investigator, Experimental model for gene delivery in the brain. (Del la Monte S, Sampath P)
Approved: 8/2000. Lifespan ARB.

Clinical Trials

Co-Principal Investigator, Protein A (Recoverin): a novel serum marker for malignant glioma. (Addendum: a marker for cell injury from cerebrovascular accident and severe head trauma) (Alderson, Sampath)
Approved: 3/2000. Rhode Island Hospital.

Co-Principal Investigator, Phase II Trial of Temozolomide and Thalidomide in newly diagnosed glioblastoma multiforme.
(Alderson LM, Sampath P)
Approved: 2001. Rhode Island Hospital.

Co-Principal Investigator, An open-label dose ranging study of the safety of Taurolidine 0.5% and 2% solutions administered intrathecally to patients with recurrent or progressive glioblastoma multiforme.
(Alderson LM, Sampath P, Calabresi P)
Approved but inactive. Rhode Island Hospital.

Co-Principal Investigator, An open-label dose ranging study of the safety of Taurolidine 0.5% and 2% solutions administered intraventricularly to patients with meningeal carcinomatosis.
(Alderson LM, Sampath P, Calabresi P)
Approved but inactive. Rhode Island Hospital.

Co-Principal Investigator, Consecutive use of interstitial chemotherapy (Gliadel) with interstitial radiotherapy (Gliasite) for recurrent malignant glioma
(Alderson LM, Sampath P)
Approved: 2002. Rhode Island Hospital.

Co-Principal Investigator, Oral ST1481 in adults with recurrent malignant glioma
(Alderson LM, Sampath P)
Approved: 2002. Rhode Island Hospital.

Principal Investigator, Consecutive treatment of recurrent malignant glioma with interstitial brachytherapy (Gliasite) and interstitial chemotherapy (Gliadel)
Approved: 2003. Rhode Island Hospital.

Co-Principal Investigator, Combination interstitial chemotherapy (Gliadel) and Irinotecan (CPT-11) in the treatment of recurrent malignant glioma.

(Alderson LM, Sampath P)
Approved: 2003. Rhode Island Hospital.

Co-Principal Investigator, Combination systemic and interstitial chemotherapy (Gliadel) in the initial treatment of malignant glioma.

(Alderson LM, Sampath P)
Approved: 2004. Rhode Island Hospital.

Principal Investigator, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin On Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery.

(Sampath P)
Approved: 2006. Roger Williams Medical Center.

Principal Investigator, Randomized Controlled Trial of Duragen Plus Adhesion Barrier Matrix to Minimize Adhesions Following Lumbar Discectomy.

(Sampath P)
Approved: 2006. Roger Williams Medical Center.

Co-Principal Investigator, Secure-C IDE.
(Palumbo M, Sampath P)

Approved: 2006. Rhode Island Hospital.

RESEARCH EXPERIENCE

- | | |
|---------------|--|
| 1985 | Victor Corces, Ph.D.
Department of Biology
Johns Hopkins University,
Baltimore, MD 21231 |
| 1985 - 1990 | Thomas .D. Pollard, M.D.
Professor and Chairman
Department of Cell Biology and Anatomy
Johns Hopkins School of Medicine,
Baltimore, MD 21205 |
| 1991 - 1992 | Jeffery N. Bruce, M.D.
Associate Professor of Neurosurgery
Bartoli Brain Tumor Laboratory
Department of Neurological Surgery
Columbia University College of Physicians and Surgeons,
New York, NY 10032 |
| 1996 - 1999 | Henry Brem, M.D.
Harvey Cushing Professor of Neurosurgery and Oncology
Director, Department of Neurological Surgery
Hunterian Fellow in Neuro-Oncology
Johns Hopkins School of Medicine
Baltimore, MD 21287 |
| 1996 - 1999 | Drew Pardoll M.D., Ph.D.
Professor of Oncology
Department of Oncology
Johns Hopkins School of Medicine
Baltimore, MD 21287 |
| 1999 - 2004 | Co-Director, Neuro-Oncology Laboratory
Aldrich Bldg 425
Rhode Island Hospital
Brown University School of Medicine
Providence, RI 02906 |
| 2004 -present | Director, Neurosurgical Brian Tumor Laboratory
50 Maude Street
Roger Williams Medical Center
Providence, RI 02908 |

PATENTS / DISCLOSURES

Endotracheal Tube (Neurosurgical). U.S. Patent No. 7,174,894.

Endotracheal Tube (Neurosurgical). U.S. Patent No. 6,874,504.

Frameless Burr Hole Stereotactic Device (CFBSD) - Pending
Inventors: Benjamin S. Carson, Prakash Sampath M.D.

Interbody Stabilization Device with Local Radiotherapy for Spinal Metastases (Proxima Therapeutics, Inc., Atlanta, GA) – Patent Pending
Inventor: Prakash Sampath M.D.

Oscillating Bipolar Blade for Brain Tumor Extirpation (Endius Corp., N. Attleboro, MA)
Inventor: Prakash Sampath M.D.

Surgical Advisory Board. (Globus Medical. Paoli, PA). 2004 – Present.

Speaking Faculty. (MGI Pharmaceuticals. Baltimore, MD). 2001– Present.

Dynamic Cervical Plating System, ABC. (Aesculap Corp., Tuttlingen, Germany). Surgical Design Team.
2002 – Present.

Anti-adhesive Collagen Sponges after Spinal Surgery. Designer. (Integra Neurosciences, Plainsboro, NJ).
2004 – Present.